These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32393291)

  • 1. Wearable cardioverter-defibrillator as bridging to ICD in pediatric hypertrophic cardiomyopathy with myocardial bridging - a case report.
    Kurath-Koller S; Sallmon H; Scherr D; Bisping E; Burmas A; Knez I; Koestenberger M
    BMC Pediatr; 2020 May; 20(1):207. PubMed ID: 32393291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
    Andresen H; Sasko B; Patschan D; Pagonas N; Ritter O
    J Med Case Rep; 2021 May; 15(1):243. PubMed ID: 33993888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apical aneurysm and myocardial bridging in a patient with hypertrophic cardiomyopathy: association or consequence of the myocardial bridging?
    Foucault A; Hilpert L; Hédoire F; Saloux E; Gomes S; Pellissier A; Scanu P; Champ-Rigot L; Milliez P
    Cardiol J; 2012; 19(6):643-5. PubMed ID: 23224930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients.
    Spar DS; Bianco NR; Knilans TK; Czosek RJ; Anderson JB
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006163. PubMed ID: 29945928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.
    Daimee UA; Vermilye K; Moss AJ; Goldenberg I; Klein HU; McNitt S; Zareba W; Kutyifa V
    Heart Rhythm; 2018 Sep; 15(9):1379-1386. PubMed ID: 29678779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophic cardiomyopathy: the importance of arrhythmic events in patients at risk for sudden cardiac death.
    Medeiros Pde T; Martinelli Filho M; Arteaga E; Costa R; Siqueira S; Mady C; Piegas LS; Ramires JA
    Arq Bras Cardiol; 2006 Nov; 87(5):649-57. PubMed ID: 17221043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes during and after the use of the wearable cardioverter-defibrillator in a tertiary-care and a regional hospital in Switzerland.
    Kovacs B; Reek S; Saguner AM; Krasniqi N; Eriksson U; Duru F
    Swiss Med Wkly; 2019 Nov; 149():w20136. PubMed ID: 31707723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
    Kutyifa V; Vermilye K; Daimee UA; McNitt S; Klein H; Moss AJ
    Europace; 2018 Sep; 20(FI2):f225-f232. PubMed ID: 29905788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?
    Barsheshet A; Vamvouris T; Goldenberg I
    Expert Rev Med Devices; 2016 Jul; 13(7):627-32. PubMed ID: 27333818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between myocardial bridging and fatal ventricular arrhythmias in patients with hypertrophic cardiomyopathy: the HCM-MB study.
    Güner A; Atmaca S; Balaban İ; Türkmen İ; Çeneli D; Türkvatan A; Öner E; Sürgit Ö; Güler A; Uzun F; Babür Güler G; Kahraman S; Pala S; Havan N; Yıldız M; Ertürk M
    Herz; 2023 Oct; 48(5):399-407. PubMed ID: 37081129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death.
    Sasaki S; Tomita H; Shibutani S; Izumiyama K; Higuma T; Itoh T; Sasaki K; Horiuchi D; Kimura M; Okumura K
    Circ J; 2014; 78(12):2987-9. PubMed ID: 25366562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.